Renol Polychem IPO Listing: Stock Lists at 5% Discount on NSE SME

Renol Polychem IPO Listing: Flat Opening Followed by Lower Circuit – Investors Face Immediate Shock on Day One

Renol Polychem’s ₹25.77 crore Initial Public Offering (IPO) hit the market with high hopes, but its listing performance has been anything but impressive. The stock opened on the National Stock Exchange (NSE) SME platform on August 7, 2023, at its offer price of ₹105 per share.

However, the excitement soon turned to disappointment as the stock struggled throughout the trading day, ultimately hitting the lower circuit limit and closing at ₹99.75, marking a 5% loss for IPO investors on Day One.

Despite an encouraging response during the subscription phase, the company’s listing has raised concerns and left investors questioning the company’s immediate prospects.

Renol Polychem IPO Overview:

Renol Polychem, incorporated in 2008, manufactures and supplies color masterbatches, plastic masterbatches, industrial chemicals, impact modifiers, and plastic pigments.

The company’s products cater to a wide range of industries, particularly plastic manufacturers who produce UPVC and CPVC pipes and other plastic fittings.

The company’s color masterbatches come in an array of hues, including green, red, yellow, pink, and violet, as well as transparent fillers.

The IPO was open for subscription from July 31 to August 4, 2023, and aimed to raise ₹25.77 crore. The funds raised would primarily be used for working capital requirements, debt reduction, and machinery upgrades to expand production capacity.

The IPO saw an enthusiastic response, being subscribed 6.83 times overall, which was a positive sign during the subscription phase. Despite the strong demand, the company’s stock did not manage to impress on its first trading day.

IPO Subscription Details and Market Reception:

During the subscription period, the Renol Polychem IPO received significant interest across various categories:

• Qualified Institutional Buyers (QIBs): Subscribed 8.41 times
• Non-Institutional Investors (NIIs): Subscribed 6.89 times
• Retail Investors: Subscribed 6.51 times

These figures indicated a healthy demand for the company’s shares, with institutional investors showing the highest level of interest. However, this enthusiasm did not translate into a positive listing performance.

When Renol Polychem’s shares began trading on the NSE SME platform, they opened flat at the IPO price of ₹105.

While flat listings aren’t uncommon in the IPO market, they are rarely seen as a sign of strong investor sentiment.

Things took a more disappointing turn when the stock quickly hit the lower circuit limit of ₹99.75, limiting the potential for any gains on the first day of trading.

The stock remained stuck at this level until market close, resulting in a 5% loss for investors who had purchased the stock at the issue price.

Understanding the Lower Circuit:

In Indian stock markets, the circuit limit is a regulatory measure designed to curb extreme volatility in stock prices within a single trading session.

For stocks listed on the NSE SME platform, the lower circuit is typically set at a 5% drop from the stock’s issue price.

In Renol Polychem’s case, this meant that once the stock dipped to ₹99.75, trading was halted at that price for the remainder of the session. This left investors unable to recover any losses during the day, and the stock closed at the same level.

A lower circuit on Day One of listing is a worrying sign. It suggests that market participants may have underestimated the company’s ability to deliver value post-IPO or that there is a mismatch between investor expectations and the company’s current fundamentals.

Given the high levels of subscription, especially from institutional buyers, the sudden drop in stock price is particularly concerning.

How Will Renol Polychem Use the IPO Funds?

Renol Polychem’s IPO raised ₹25.77 crore, and the company has outlined specific plans for how these funds will be used to enhance its operations and financial position. The allocation of the raised capital is as follows:

• ₹5.6 crore for machinery purchase: This will allow Renol Polychem to upgrade and expand its manufacturing capabilities, ensuring it can meet growing demand and improve product quality.
• ₹1 crore for debt reduction: The company aims to use part of the IPO proceeds to reduce its existing liabilities, which would help in improving its financial stability and reduce interest burden.
• ₹15.15 crore for working capital needs: This allocation will ensure that the company can cover day-to-day operational expenses, maintain inventory, and streamline its supply chain, which is critical for business continuity.
• The remaining funds will be used for general corporate purposes, which could encompass a range of operational, strategic, or marketing activities to strengthen its market position.

Renol Polychem’s Business Model and Market Position:

Renol Polychem’s business revolves around providing high-quality colorants and additives to manufacturers in the plastic industry.

Its masterbatches are used in various applications, including the production of pipes, fittings, and other plastic goods.

The company also produces impact modifiers, stabilizers, and plastic pigments, all of which play crucial roles in improving the strength and durability of plastic products.

The company caters to a range of industries, from construction to automotive, providing essential raw materials for plastic manufacturers.

With an established product portfolio and a growing reputation in the polymer industry, Renol Polychem is well-positioned to capitalize on the increasing demand for colored plastics and additives.

The global plastics market is expected to grow at a steady pace, driven by the expanding use of plastic in multiple sectors, which bodes well for the company’s long-term prospects.

Financial Performance: Past and Present

Renol Polychem’s financial performance over the past few years has been improving, with the company reporting steady growth in profits:

• FY 2023 Profit: ₹7.3 lakh
• FY 2024 Profit: ₹1.53 crore
• FY 2025 (Projected) Profit: ₹5.00 crore

However, while the company’s profitability has improved, debt levels have remained a concern:

• FY 2023 Debt: ₹5.36 crore
• FY 2024 Debt: ₹2.58 crore
• FY 2025 (Projected) Debt: ₹6.95 crore

Despite the growth in profits, Renol Polychem’s rising debt levels suggest that the company has been relying on borrowed funds for expansion. The use of IPO proceeds for debt reduction will be a key factor in improving the company’s financial health.

In the current FY 2026, Renol Polychem has reported a profit of ₹1.14 crore in the first two months (April-May 2025), indicating a positive start to the year.

Additionally, the company has successfully reduced its debt to ₹5.28 crore, signaling progress in improving its financial structure.

Investor Outlook and Future Prospects

The flat listing and subsequent drop in share price on Day One have cast a shadow over Renol Polychem’s future in the market.

However, it is still early days for the company, and long-term investors may want to look at its strategic plans, including the use of IPO funds for machinery upgrades, debt reduction, and working capital enhancement.

If the company can leverage these funds effectively, it may be able to turn its fortunes around.

The global plastic market, which is poised for continued growth, presents a substantial opportunity for companies like Renol Polychem, but the company will need to maintain consistent performance in terms of both profitability and debt management to keep investor confidence intact.

For now, investors are watching closely. Will Renol Polychem’s stock recover in the coming weeks, or will it continue to struggle under the weight of its debt and disappointing listing? Time will tell, but the next few months will be critical for the company’s long-term trajectory.